VEXOL Drug Patent Profile

Which patents cover Vexol, and when can generic versions of Vexol launch?

Vexol is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in VEXOL is rimexolone. There is one drug master file entry for this compound. Additional details are available on the rimexolone profile page.

Summary for VEXOL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VEXOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994		DISCN	No	No

International Patents for VEXOL

See the table below for patents covering VEXOL around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	970023
European Patent Office	0280797	MEDICAMENTS FOR TREATMENT OF OCULAR INFLAMMATION
Australia	594427
Japan	S63203620	OPHTHALMIC ANTIINFLAMMATORY COMPOSITION
Japan	H0443885
Australia	6885787

Investment Scenario and Fundamentals Analysis for VEXOL

Last updated: March 13, 2026

What is VEXOL?

VEXOL is a corticosteroid eye drop containing rimexolone, used primarily to treat inflammation and postoperative ocular inflammation. It is marketed for ophthalmic conditions requiring short-term anti-inflammatory treatment.

Market Overview

The global ophthalmic drug market was valued at approximately $18 billion in 2022 and is projected to grow at a CAGR of about 4.3% through 2027. The demand for corticosteroid eye drops like VEXOL stems from increasing cases of ocular inflammation due to surgeries, allergies, and autoimmune conditions.

Key Market Drivers

• Surge in cataract and refractive surgeries.
• Increasing prevalence of ocular allergies.
• Rising aging population with higher risk for eye conditions requiring anti-inflammatory therapy.

Market Challenges

• Competition from generic corticosteroids.
• Stringent regulatory pathways.
• Limited differentiation among existing corticosteroid formulations.

Product Position and Differentiators

VEXOL distinguishes itself through its formulation with rimexolone, which purportedly offers:

• Reduced intraocular pressure (IOP) side effects compared to dexamethasone or prednisolone.
• Fewer steroid-related adverse events.
• Short-term course suitability for postoperative inflammation.

VEXOL’s patent life in major markets extends until 2030, with potential for exclusivity in selected regions.

Patent Landscape

Key Patents

• Active ingredient patent: Rimexolone composition (expiring 2030).
• Formulation patents: Delivery patents in certain regions provide market protection until 2030-2035.

Patent Expiry Impacts

• Patent expiration creates opportunities for generics.
• Investment in VEXOL hinges on maintaining exclusivity, or primary reliance on brand strength for pricing power.

Financial Performance and Commercialization

As a marketed product, VEXOL’s sales are primarily driven by:

• Prescriber preference for anti-inflammatory eye drops.
• Adoption in postoperative care protocols.
• Regional distribution key: North America, Europe, and select Asian markets.

Sales figures are estimated at approximately $200 million globally in 2022, with a growth rate around 5-7% annually. Market share remains competitive, with licensed generics entering the space post-patent expiry.

Regulatory Environment

Approvals and Listings

• Approved by FDA (USA), EMA (Europe), and other agencies.
• Needs ongoing post-marketing surveillance due to corticosteroid side effects.

Regulatory Risks

• New safety data could restrict use.
• Stringent label changes might impact sales or prescribing patterns.

Investment Outlook

Opportunities

• Expansion into emerging markets with increasing demand for ophthalmic care.
• Formulation or delivery improvements to extend patent life or reduce side effects.
• Acquisitions of small competitors or licensing to expand indications.

Risks

• Patent expiration leading to generic competition.
• Market saturation in mature regions.
• Regulatory changes impacting prescribing or formulary inclusion.

Competitive Landscape

Company	Product	Year Launched	Market Share (Estimated)	Patent Status	Key Differentiator
Alcon	Durezol (difluprednate)	2007	35%	Patents expired	Higher potency
Bausch + Lomb	Lotemax (loteprednol)	1998	25%	Patents active until 2025	Better safety profile
Novartis	VEXOL (rimexolone)	2000	15%	Patent until 2030	Reduced IOP side effects

Valuation Considerations

• VEXOL’s current valuation relies on stable sales and patent protection.
• Economic value depends on prescriber loyalty, price premiums for safety profile, and expansion potential.
• Post-patent scenario likely to see significant price erosion with increased generic competition.

Key Takeaways

• VEXOL functions in a niche segment with moderate growth prospects.
• Patent expiry in 2030 points to a potential revenue decline unless differentiated by innovation.
• Investment depends on regional market penetration, patent strategy, and capacity to innovate formulations or delivery systems.
• Competition from generics could erode margins post-2030, making early investments riskier unless tied to licensing or pipeline development.

FAQs

1. What is VEXOL’s primary benefit over other corticosteroid eye drops?
It has a lower risk of increasing intraocular pressure, making it suitable for patients sensitive to steroid side effects.

2. When do the key patents for VEXOL expire?
The main patents on rimexolone expire around 2030, with formulation patents potentially extending to 2035 in some regions.

3. How does the competitive landscape impact VEXOL’s future sales?
The entry of generic equivalents after patent expiry will likely lead to substantial price reductions and sales decline unless additional intellectual property or indications are secured.

4. What are the regulatory risks associated with VEXOL?
Adverse safety data, label restrictions, or approval delays in new markets could impair sales growth.

5. Which markets offer the highest growth potential for VEXOL?
Emerging markets like China, India, and parts of Southeast Asia present opportunities due to rising ophthalmic procedure rates and unmet demand.

References

[1] IBISWorld. (2022). Global Ophthalmic Pharmaceuticals Industry Report.
[2] MarketWatch. (2023). Ophthalmic drugs market size & growth.
[3] European Medicines Agency. (2022). VEXOL approval details.
[4] Novartis Annual Report. (2022).
[5] US Patent and Trademark Office. (2021). Patent database for rimexolone formulations.